Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
Colette DeJong, Camlyn Masuda, Randi Chen, Dhruv S. Kazi, R. Adams Dudley, Chien‐Wen Tseng
Abstract
This study examines cost sharing for novel second-line diabetes treatment agents under Medicare Part D.
Topics & Concepts
MedicineGuidelineDiabetes mellitusIntensive care medicineMedicare Part DMEDLINEPharmacologyPathologyMedical prescriptionEndocrinologyPolitical sciencePrescription drugLawMedication Adherence and CompliancePharmaceutical Economics and PolicyPharmaceutical studies and practices